Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | IDH1 | O75874 | 1/20 | 0.49 |
| ▸ | IDE | P14735 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7913041 | 0.85 | SMN1; SMN2 (0.58) | KMT2ATSHRSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL3101805 | 0.84 | SMN1; SMN2 (0.52) | KMT2ARXFP1MAPTMAPK1MEN1 | |
| SCHEMBL7913781 | 0.83 | ALDH1A1 (0.52) | KMT2ATSHRMAPK1MEN1SMN1; SMN2 | |
| SCHEMBL7906320 | 0.81 | GRM4 (0.56) | KMT2ARXFP1MAPTMEN1SMN1; SMN2 | |
| SCHEMBL13148169 | 0.80 | KMT2A (0.53) | KMT2ARXFP1TSHRMAPTUSP2 | |
| SCHEMBL7906315 | 0.79 | NPC1 (0.56) | SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL7910114 | 0.78 | LRRK2 (0.53) | KMT2AMAPTMEN1SMN1; SMN2RAB9A | |
| SCHEMBL7909378 | 0.78 | LRRK2 (0.52) | SMN1; SMN2RAB9ANPC1 | |
| SCHEMBL13561074 | 0.77 | KMT2A (0.72) | KMT2ATSHRMAPTUSP2IDE | |
| SCHEMBL7909381 | 0.77 | LRRK2 (0.57) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010100050-A1 | PYRIDINE-2-YL-CARBOXYLIC ACID AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-10 | — | — | WO | disclosed |
| US-20100227887-A1 | PYRIDINE-2-YL CARBOXYLIC ACID AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227887-A1 | PYRIDINE-2-YL CARBOXYLIC ACID AMIDES | GRM2, GRM1, GRM3 | KMT2A 652/4885RXFP1 216/4885TSHR 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.